ted ziemann; chairman and chief executive officer at armis biopharma

Theodore Ziemann
Chairman and Chief Executive Officer

He was re-appointed CEO in March 2018. He has served as Chairman of the Board of Directors of Armis Biopharma® and predecessor companies, Chata and CHD Bioscience since March 2000. He previously served as Chairman and Chief Executive Officer from August 2007 through November 2012.

Mr. Ziemann has over 45 years of experience in the life science industry, leading large geographically disbursed teams across multiple disciplines, including general management, marketing, manufacturing, and engineering in North and South America, Europe, and Asia.

Mr. Ziemann served as global President of the Health and Food Technologies business of Cargill, Inc., from May 2000 through May 2006, and served on the leadership team of the North American Food Sector. He served on the Consumer Health Products Association Board during 2001-2006 and on the Council of Responsible Nutrition Board during 2001-2006.

From 1990 to 1999, he led various global multifunctional divisions for Rhone-Poulenc, SA, the French life science and chemical company, where he served as Sr. Executive Vice President of the global Plant and Animal Health and Nutrition Sector from 1998 to 1999 (Acquired by Bayer AG (FWB: BAYN) and Sanofi SA (SNY)); President of Rhone-Poulenc Ag Company from 1996 to 1998; President of the global Fine Chemical Division from 1993 to 1996. (Acquired by Solvay SA (Euronext: SOLB)); and Sr. Vice President of Manufacturing, Engineering, Safety and Quality for North America from 1990 to 1993. He also served as a member of Rhone-Poulenc’s Senior Corporate Technology Council from 1990 to 1999. In addition to his business leadership, Mr. Ziemann oversaw all of the global manufacturing, industrial technology, quality management, and safety, environmental and health activities for two separate $5 billion sectors.

Mr. Ziemann led various global director level positions in manufacturing, marketing, and engineering for Monsanto Company (Acquired by Bayer AG) from 1970 to 1990.

Mr. Ziemann has a B.S. in Chemical Engineering from Iowa State University and an Executive M.B.A. from the University of Iowa. He also participated in the Executive Group Management Program at INSEAD (Fontainebleau, France) in cooperation with Rhone- Poulenc’s Executive Committee.

Mr. Ziemann brings deep global senior executive management experience in the life science industry, as well as strong strategic, manufacturing, technology development, quality management, and engineering expertise.